LakePharma cited in 2014 publication of Protein Expression and Purification

Added On: 2013-11-08

LakePharma was recently credited for its role with affinity measurements of the soluble production of biologically active single-chain antibodies against murine PD-L1 in Escherichia coli (E. coli). LakePharma calculated the binding kinetics (affinity measurements) of the surface plasmon resonance (SPR) using the ForteBio Octet QKe system. The study concluded that αPD-L1 scFv is an attractive alternative to full-length mAb for blocking PD-1/PD-L1 signaling for experimental purposes.
 

For more information on LakePharma’s role in this study, view the article:

Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coli.

Drees JJ, Augustin LB, Mertensotto MJ, Schottel JL, Leonard AS, Saltzman DA.

Protein Expr Purif. 2014 Feb;94:60-6.